These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37669868)
1. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study. Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH; Calimlim BM; Takemoto S; Sancho C; Fritz B; Irvine AD J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):340-353. PubMed ID: 37669868 [TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study. Gkalpakiotis S; Kannenberg S; Kingo K; Nada HR; Rakhmatulina MR; Lesiak A; Nicolescu AC; Darlenski R; Masri A; Zhou L; Albuquerque T; Hammad S; Almasry I Dermatol Ther (Heidelb); 2024 May; 14(5):1173-1187. PubMed ID: 38702528 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005 [TBL] [Abstract][Full Text] [Related]
4. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry. Guttman-Yassky E; Bar J; Rothenberg-Lausell C; Eichenfield L; Grada A; Abuabara K; Chapman M; Calimlim B; Wegzyn C; Gamelli A; Krueger W; Munoz B; Knapp K; Faller R; Crawford J; Silverberg J J Drugs Dermatol; 2023 Apr; 22(4):344-354. PubMed ID: 37026893 [TBL] [Abstract][Full Text] [Related]
5. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis. Anderson P; Austin J; Lofland JH; Piercy J; Joish VN Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709 [TBL] [Abstract][Full Text] [Related]
6. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354 [TBL] [Abstract][Full Text] [Related]
7. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment. Wei W; Ghorayeb E; Andria M; Walker V; Schnitzer J; Kennedy M; Chen Z; Belland A; White J; Silverberg JI Ann Allergy Asthma Immunol; 2019 Oct; 123(4):381-388.e2. PubMed ID: 31325566 [TBL] [Abstract][Full Text] [Related]
8. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222 [TBL] [Abstract][Full Text] [Related]
9. Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study. Darbellay B; Huber M; Bisschoff IJ; Guillod C; Hügel R; Pirkhammer D; Sator PG; Taskesen T; Lang CCV J Dermatolog Treat; 2024 Dec; 35(1):2415407. PubMed ID: 39419511 [TBL] [Abstract][Full Text] [Related]
10. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163 [TBL] [Abstract][Full Text] [Related]
11. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. Simpson EL; Bieber T; Eckert L; Wu R; Ardeleanu M; Graham NM; Pirozzi G; Mastey V J Am Acad Dermatol; 2016 Mar; 74(3):491-8. PubMed ID: 26777100 [TBL] [Abstract][Full Text] [Related]
12. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437 [TBL] [Abstract][Full Text] [Related]
13. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial. Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175 [TBL] [Abstract][Full Text] [Related]
14. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791 [No Abstract] [Full Text] [Related]
15. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort. Silverberg JI; Simpson B; Abuabara K; Guttman-Yassky E; Calimlim B; Wegzyn C; Krueger W; Gamelli A; Munoz B; Faller RW; Crawford JM; Grada A; Eichenfield LF; J Am Acad Dermatol; 2023 Sep; 89(3):519-528. PubMed ID: 37150299 [TBL] [Abstract][Full Text] [Related]
16. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421 [TBL] [Abstract][Full Text] [Related]
17. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. de Bruin-Weller M; Gadkari A; Auziere S; Simpson EL; Puig L; Barbarot S; Girolomoni G; Papp K; Pink AE; Saba G; Werfel T; Eckert L J Eur Acad Dermatol Venereol; 2020 May; 34(5):1026-1036. PubMed ID: 31587373 [TBL] [Abstract][Full Text] [Related]
18. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry. Silverberg JI; Pierce E; Feely M; Atwater AR; Schrader A; Jones EA; Dave SS; Simpson EL J Dermatolog Treat; 2023 Dec; 34(1):2246601. PubMed ID: 37691405 [TBL] [Abstract][Full Text] [Related]
19. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis. Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179 [TBL] [Abstract][Full Text] [Related]
20. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis]. Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]